GlassScriptPhysician profile
James B Hancock
NPI 1235116088
$3,953.10
in general payments reported to CMS, 2019-2025
35 companies · $1,568 in 2025
The $1,568 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $11.14 · 2021: $60.67 · 2022: $66.14 · 2023: $546 · 2024: $1,292 · 2025: $1,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,405.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $517.43 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $443.27 | 2019-2025 | |
| Lilly USA, LLC | $248.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $240.22 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Dexcom, INC. | $192.36 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $166.67 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Boston Scientific Corporation | $152.39 | 2024-2025 | Watchman Access System |
| Phathom Pharmaceuticals, INC. | $121.07 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $111.43 | 2023-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $105.33 | 2024-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $104.96 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $91.75 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.76 | 2023-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $79.56 | 2025 | Zoryve |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $64.22 | 2019 | |
| Idorsia Pharmaceuticals US INC | $55.48 | 2023 | Quviviq |
| Insulet Corporation | $49.62 | 2024 | Omnipod |
| Merck Sharp & Dohme LLC | $43.24 | 2019-2023 | Vaxneuvance, Gardasil 9 |
| Abbott Laboratories | $43.06 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $42.35 | 2024 | |
| Corcept Therapeutics | $36.68 | 2019-2025 | Korlym |
| Amgen INC. | $29.95 | 2023-2025 | Repatha, Prolia, Evenity |
| Axsome Therapeutics, INC. | $26.40 | 2025 | Symbravo |
| Biodelivery Sciences International, INC. | $25.40 | 2019 | |
| Mylan Specialty L.P. | $23.88 | 2024 | Yupelri |
| Endo Pharmaceuticals INC. | $19.94 | 2023 | Xiaflex, Aveed |
| Astellas Pharma US INC | $19.65 | 2024 | Veozah |
| Phadia US INC. | $16.10 | 2023 | Immunocap |
| Sanofi-Aventis U.S. LLC | $15.26 | 2023 | |
| Aimmune Therapeutics, INC. | $14.98 | 2025 | Zenpep |
| Almatica Pharma LLC | $13.40 | 2023 | Loreev Xr, Gralise |
| Supernus Pharmaceuticals, INC. | $12.54 | 2022 | |
| Ironshore Pharmaceuticals INC. | $11.77 | 2019 | |
| Antares Pharma, INC. | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hancock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.